Noubar Afeyan - BG Medicine Insider

BGMD -- USA Stock  

USD 0.03  0.009  42.86%

Dr. Noubar B. Afeyan Ph.D. is an Independent Director of BG Medicine Inc. since July 25 2011. He is founder and served as the Board of Directors since inception in 2000. He has served as Managing Partner and Chief Executive Officer of Flagship Ventures an early stage VC firm since he cofounded the firm in 2000. Prior to founding Flagship Ventures in 2000 Dr. Afeyan participated in cofounding and helping launch the following ventures PerSeptive Biosystems ChemGenics Pharmaceuticals EXACT Sciences Agenus Color Kinetics and Celera Genomics. Dr. Afeyan was Chief Executive Officer of PerSeptive Biosystems during its five years as a public company and until its merger with Perkin Elmer Corporationrationration. During the past five years Dr. Afeyan has served on the board of directors of Helicos BioSciences. Additionally he currently serves as a director of the following private companies Affinnova Inc. Aero Designs BIND Therapeutics Inc. Eleven Biotherapeutics Ensemble Therapeutics Joule Unlimited Inc. LS9 Inc. Moderna Therapeutics and Pronutria. He earned his Ph.D. in biochemical engineering from the Massachusetts Institute of Technology following a B.S. in chemical engineering from McGill University. Dr. Afeyan has authored numerous scientific publications and patents and is currently a Senior Lecturer at MIT in the Sloan School of Management
Age: 52  Founder Since 2011      

Noubar Afeyan Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (75.95) % which means that it has lost $75.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (902.64) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG Medicine operates under Diagnostics Research classification in USA and traded on OTC Market. It employs 5 people.BG Medicine (BGMD) is traded on OTC Market in USA. It is located in 303 Wyman Street and employs 5 people.

BG Medicine Leadership Team

James Connor, Director
Harry Wilcox, Director
Stelios Papadopoulos, Independent Director
Aram Adourian, Chief Scientific Officer and Sr. VP
Stephen Hall, CFO, Principal Accounting Officer, Executive VP and Treasurer
Jeffrey Luber, Director
Paul Sohmer, President CEO, Director
Noubar Afeyan, Founder
James OConnor, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio Manager Now


Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Portfolio Manager

BG Medicine Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for BG Medicine and Illumina. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.